The U.S. Food and Drug Administration (FDA) has granted fast-track designation to CK0803, an experimental T-cell therapy from Cellenkos that’s currently in Phase 1 clinical testing for people with amyotrophic lateral sclerosis (ALS). The designation aims to accelerate the clinical development and regulatory review of new treatments that…
News
ALN-SOD, an experimental RNA-based therapy being developed for a genetic subtype of amyotrophic lateral sclerosis (ALS) called SOD1-ALS, showed an “encouraging” safety profile and preliminary signs of potential efficacy, according to early results from a Phase 1b/2 study. Biomarker data from participants in the first-in-human Phase 1b/2 GOALS…
For Emmy award-winning host and New York Times bestselling author Tabitha Brown, joy, gratitude, and hope have guided her through life since losing her mother to amyotrophic lateral sclerosis (ALS) in 2007. Speaking this week at the ALS Nexus conference in Orlando, Florida, and online, Brown shared how…
An experimental implantable device from Precision Neuroscience enabled computers to decode brain signals to predict movement and speech, which could eventually help create assistive devices for people with amyotrophic lateral sclerosis (ALS). That’s according to findings from preliminary tests conducted in patients undergoing routine neurosurgical procedures, which were…
People with diabetes may be less likely to develop amyotrophic lateral sclerosis (ALS) than those without diabetes, according to findings detailed in a poster presented at the ALS Nexus conference. The study also found that people with a longer reported duration of diabetes and those receiving insulin as…
The ALS Association has awarded Mitochon Pharmaceuticals a $1 million grant to support a Phase 2 clinical trial testing the company’s experimental therapy MP-101 in people with amyotrophic lateral sclerosis (ALS). The study is still in the planning stages and is expected to kick off next year.
Higher levels of physical activity were associated with a lower risk of developing amyotrophic lateral sclerosis (ALS) in a large U.K. study. The association was seen using both self-reported activity questionnaires and objective measurements from wrist-worn devices called accelerometers. Among participants with known genetic risk factors for ALS,…
A modified frailty index based on five self-reported health measures may help identify people at higher risk of developing amyotrophic lateral sclerosis (ALS), according to a new study. The model, which included falls, whole-body pain, long-standing illness or disability, self-rated health, and tiredness or lethargy in the previous two…
Stem cell therapies are generally safe and well tolerated in people with amyotrophic lateral sclerosis (ALS), and preliminary evidence from clinical trials suggests they may also help slow functional decline, according to a systematic review and meta-analysis of several published studies. Researchers found that people given stem cell therapies…
Loneliness and regret are key drivers of mental health distress among people with amyotrophic lateral sclerosis (ALS), according to a new survey — but the researchers also found that maintaining a hopeful outlook may help those with the rare disease to combat anxiety, depression, and frustration. The survey,…
Recent Posts
- Experimental treatment shows promise in patient with rare genetic form of ALS
- Measuring levels of toxic protein in blood may help diagnose ALS
- Despite being paralyzed by ALS, my husband doesn’t dwell on the disease
- From clothing to handwriting, I’m still adapting to ALS and cultural change
- Better cardiovascular health linked to lower ALS risk in large study